Approval Background and Demonstration of Clinical Equivalence

Viatris (VTRS), a global pharmaceutical company, has received final approval from the European Medicines Agency (EMA) for Mysildecard, a generic treatment for pulmonary arterial hypertension (PAH). Following the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on July 28, 2016, the European Commission (EC) granted the final marketing authorization on September 15, 2016. This approval is the result of demonstrating bioequivalence to Pfizer's (PFE) original treatment, Revatio. Having passed the rigorous scientific assessment by regulatory authorities, its efficacy and safety have been sufficiently verified, providing a great alternative to replace the original drug.

Mechanism of Action and Value in Treating Pulmonary Arterial Hypertension

The active ingredient in Mysildecard, sildenafil, belongs to the phosphodiesterase type 5 (PDE5) inhibitor class and has a mechanism of action that induces vasodilation in the pulmonary vessels. By blocking the activity of the PDE5 enzyme, it promotes relaxation of the pulmonary vascular smooth muscle and lowers pulmonary artery pressure, thereby reducing the burden on the heart. This drug has demonstrated excellent efficacy in improving exercise capacity and hemodynamic parameters in PAH patients across a wide age range, from children aged one year and older to adults. By providing high-quality medicines in a rare disease area where continuous treatment is directly related to prognosis, it contributes to improving the quality of life for patients.

Positioning Compared to the Original and Competitive Landscape

Mysildecard is competing head-on in the European sildenafil market, which was previously dominated by Pfizer's Revatio, by offering a reasonable pricing strategy. It forms a competitive landscape with Eli Lilly's (LLY) Adcirca (active ingredient: tadalafil) and Johnson & Johnson's (JNJ) high-priced endothelin receptor antagonist (ERA) treatment, Opsumit (active ingredient: macitentan). It offers an affordable alternative that significantly improves access for patients who have hesitated to undergo treatment due to the high cost of the drug. It also positions itself as an attractive option for health authorities in various European countries, considering the health of the financial system, by providing cost-saving effects.

European Reimbursement Barriers and Challenges for Local Market Penetration

Even after obtaining approval from the European Medicines Agency, there remains a practical hurdle in the form of reimbursement negotiations with the healthcare insurance systems of each member state. European countries conduct independent economic evaluations to determine drug prices, so there is a risk that the initial market penetration rate will vary by country. To accelerate market penetration, Viatris needs to strengthen distribution channels in major specialized hospitals and present academic data to convince healthcare professionals. Securing strong negotiating power for local drug prices and maintaining a robust supply chain will be key to successfully replacing the original drug's market share.

Market Size of Pulmonary Arterial Hypertension and Business Prospects

The global market size for pulmonary arterial hypertension is approximately $8.0 billion to $8.5 billion (USD) by 2025, and the European market accounts for approximately 28% of this, or $2.11 billion (USD). In a market environment that is growing by more than 5% per year, Viatris has secured a long-term and stable cash cow through Mysildecard. This approval has strengthened Viatris' cardiovascular pipeline competitiveness and diversified its portfolio as a global generic leader. By utilizing efficient large-scale production systems and European supply chains, it will be possible to overcome the margin pressure of generics and maximize profitability.